


**Current Listing of Claims:**


This listing of claims, with markings to show any changes made, will replace all prior versions, and listings, of claims in the application.

1. (Withdrawn-Currently Amended) A method for treating anxiety in a patient in need of said treatment comprising orally administering to said patient as an active ingredient, an anti-anxiety compound of the formula



or a pharmaceutically acceptable salt thereof,

at a daily oral dosage of from about 50 to about 250 mg, ~~with wherein~~ said daily oral ~~dose~~ ~~having dosage comprises~~ a first portion of the active ingredient in ~~an~~ a rapid release form and the remaining portion of said active ingredient in a sustained release form, ~~said proportion and wherein the amount of said active ingredient in the rapid release form administered being~~ ~~is~~ from about 1 to about 4 times ~~14~~ the weight of the ~~portion administered~~ active ingredient in the sustained release form.



2. (Withdrawn-Currently Amended) The method of claim 1, wherein the daily oral dosage ~~dose~~ is administered in from 1 to 3 administrations per day.

3. (Withdrawn-Currently Amended) The method of claim 1, wherein said active ingredient is administered as ~~2~~ tablets.

4. (Withdrawn-Currently Amended) The method of claim 2, wherein for each of said separate administrations, the 2 sustained release portion is administered in combination with the rapid release portion.

5. (Withdrawn-Currently Amended) The method of claim 4, wherein the daily des oral dosage of said anti-anxiety compound is from about 120 to about 240 mg.

6. (Withdrawn-Currently Amended) The method of claim 5, wherein in for each of said administrations the proportion amount of said active ingredient in the rapid release portion form is about 2.5 2.5 to 3.5 times the weight of the portion active ingredient in the slow sustained release portion.

7. (Withdrawn-Currently Amended) The method of claim 3, wherein in each of said administrations the slow sustained release portion is administered together with the rapid release portion portions.


8. (Withdrawn-Currently Amended) The method of claim 7, wherein in each of said administrations, the slow sustained release portion and the rapid release portion are administered in a single tablet.

9. (Withdrawn-Currently Amended) The method of claim 8, wherein said tablet contains the active ingredient in rapid release form in an amount of about 3 times the weight of the active ingredient slow in sustained release form.

10. (Withdrawn-Currently Amended) The method of claim 9, wherein the tablets administered contain tablet contains about 10 mg of the active ingredient in its sustained release form and about 30 mg of the active ingredient in its rapid release form.


11. (Withdrawn) The method of claim 9 wherein the tablets administered contain tablet contains about 30 mg of the active ingredient in its sustained release form and about 90 mg of the active ingredient in its rapid release form.

12. (Currently Amended) A pharmaceutical oral unit dosage form comprising two separate compartments each containing a composition ~~comprised which comprises as~~ a pharmaceutically active ingredient ~~selected from the group consisting of the~~ a compound of the formula



~~and or~~ a pharmaceutically acceptable salt thereof

~~in a mixture with and~~ a pharmaceutically acceptable carrier, said active ingredient being present in the unit dosage form in an amount of from about 50 to about 250 mg, with the amount of said active ingredient in the first compartment being from about 1 to about 4 times the weight of said active ingredient in the second compartment, and wherein the composition ~~is~~ in the first compartment ~~being~~ is adapted for rapid release of said active ingredient contained therein and the composition in the second compartment ~~having~~ has incorporated therein a hydrophilic polymeric matrix which causes sustained release of the active ingredient in the second compartment.



13. (Currently Amended) The unit dosage form of claim 12 wherein the oral unit dosage form is a tablet.

14. (Currently Amended) The unit dosage form of claim 13, wherein the composition has a particle  $\geq$  size diameter of less than 250 microns.

15. (Currently Amended) The unit dosage form of claim 14, wherein the polymeric matrix is  $\geq$  hydroxypropyl methyl cellulose.

16. (Original) The unit dosage form of claim 15, wherein the pharmaceutically acceptable carrier in each of said compartments is fast flow lactose.

17. (Original) The unit dosage form of claim 14, wherein the active ingredient is present in the unit dosage form in an amount of from about 80 to about 240 mg.

18. (Currently Amended) The unit dosage form of claim 17, wherein the active ingredient is present  $\geq$  in the unit dosage form in an amount of from about 120 to about 240 mg.

19. (Currently Amended) The unit dosage form of claim 18, wherein the amount of active ingredient is in the  $\geq$  rapid release portion composition is in an amount of about 2.5 to  $\leq$  3.5 times the weight of the active  $\geq$  ingredient in the sustained release composition portion.

20. (Currently Amended) The unit dosage form of claim 19, wherein the tablet contains about 30 mg  $\geq$  of the active ingredient in the sustained release form composition and about 90 mg of the active  $\geq$  ingredient in the rapid release composition form.

21. (Currently Amended) The unit dosage form of claim 20 wherein the tablet contains from about 10 mg of the active ingredient in the sustained release form composition and about 30 mg of the active ingredient in the rapid release composition form.